Results 51 to 60 of about 152,178 (350)

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.

New England Journal of Medicine, 2019
BACKGROUND Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor.
S. Modi, C. Saura, T. Yamashita, Yeon-Hee Park, Sung-Bae Kim, K. Tamura, F. André, H. Iwata, Yoshinori Ito, J. Tsurutani, J. Sohn, N. Denduluri, C. Perrin, K. Aogi, E. Tokunaga, S. Im, K. Lee, S. Hurvitz, J. Cortés, Caleb Lee, Shuquan Chen, Lin Zhang, J. Shahidi, A. Yver, I. Krop   +24 more
semanticscholar   +1 more source

Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma

Cancers, 2021
Simple Summary Overexpression of HER2 receptors have been identified in various types of cancer including breast cancer and ovarian cancer. HER2 overexpression is generally associated with poor clinical outcomes in patients with HER2-positve tumors ...
H. Maadi, Mohammad Hasan Soheilifar, Won-Shik Choi, Abdolvahab Moshtaghian, Zhixiang Wang   +4 more
semanticscholar   +1 more source

Long‐term prognosis is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status

BJS (British Journal of Surgery), EarlyView., 2020
This long‐term follow‐up study determined survival rates in a Swedish national cohort of 417 patients with breast cancer who all had neoadjuvant systemic therapy (NAST). Sentinel lymph node biopsy (SLNB) was performed before NAST in clinically node‐negative and after NAST in clinically node‐positive patients.
L. Zetterlund, F. Celebioglu, T. Hatschek, J. Frisell, J. de Boniface   +4 more
wiley   +1 more source

Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary [PDF]

, 2018
Breast Cancer (BC) skin metastases represent a challenging clinical scenario. Although they usually arise when other distant metastases are already present, they may also represent a form of locoregional recurrence (LRR). Systemic therapy in this setting
Dieci, Maria V, Evangelista, Laura, Giarratano, Tommaso, Giorgi, Carlo A, Guarneri, Valentina, Michieletto, Silvia, Miglietta, Federica, Polico, Ilaria, Tsvetkova, Vassilena   +8 more
core   +1 more source

Disrupting Circadian Rhythm via the PER1–HK2 Axis Reverses Trastuzumab Resistance in Gastric Cancer

Cancer Research, 2022
In trastuzumab-resistant HER2-positive gastric cancer, glycolysis fluctuates with a circadian oscillation regulated by the BMAL1–CLOCK–PER1–HK2 axis, which can be disrupted with a metformin-based chronotherapy to overcome trastuzumab resistance.
Jiao Wang, Qiong Huang, Xingbin Hu, Shuyi Zhang, Yu Jiang, Guangyu Yao, Kongzhen Hu, Xin Xu, B. Liang, Qijing Wu, Zhenfeng Ma, Yawen Wang, Chunlin Wang, Zhenzhen Wu, Xiaoxiang Rong, W. Liao, Min Shi   +16 more
semanticscholar   +1 more source

A Case of Corneal Melting in a Patient with HER2-Positive Breast Cancer

Case Reports in Ophthalmology, 2022
Trastuzumab is the cornerstone treatment for HER2-positive breast cancer. While ocular side effects are more commonly described after the use of the antibody-drug conjugate ado-trastuzumab emtansine, we here describe corneal melting in a 79-year-old ...
Deborah Peeters, Melissa Vereecken, Hannelore Denys, Dimitri Roels   +3 more
doaj   +1 more source

Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. [PDF]

, 2013
Data characterizing demographics, treatment patterns, and clinical outcomes in black patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) are limited.
Abidoye, Oyewale O, Brufsky, Adam M, Kaufman, Peter A, Mayer, Musa, Rugo, Hope S, Tripathy, Debu, Ulcickas Yood, Marianne, Yardley, Denise A, Yoo, Bongin   +8 more
core   +1 more source

Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer

Cancer Research, 2021
Evidence of gut microbiota involvement in trastuzumab efficacy represents the foundation for new therapeutic strategies aimed at manipulating commensal bacteria to improve response in trastuzumab-resistant patients.
Martina Di Modica, G. Gargari, V. Regondi, Arianna Bonizzi, S. Arioli, B. Belmonte, L. De Cecco, E. Fasano, F. Bianchi, A. Bertolotti, C. Tripodo, L. Villani, F. Corsi, S. Guglielmetti, A. Balsari, T. Triulzi, E. Tagliabue   +16 more
semanticscholar   +1 more source

The ErbB2 receptor in gastric cancer. the quick-change artist [PDF]

, 2015
The ErbB family of receptors is providing the oncogenic signals necessary to cells to become transformed. In gastric cancer (GC) the ErbB2 (HER2) expression is associated with a poor prognosis, but addition of ErbB-targeted therapeutics to chemotherapy ...
Alimandi, Maurizio, D'Aloia, MARIA MICHELA, Malaguti, Paola   +2 more
core   +1 more source

Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics

Journal of Ovarian Research, 2010
Background Early studies have demonstrated comparable levels of HER2/ErbB2 expression in both breast and ovarian cancer. Trastuzumab (Herceptin), a therapeutic monoclonal antibody directed against HER2, is FDA-approved for the treatment of both early and
Wilken Jason A, Webster Kristy T, Maihle Nita J   +2 more
doaj   +1 more source